The report provides a detailed analysis essential for establishing a Halometasone production plant. It encompasses all critical aspects necessary for Halometasone production, including the cost of Halometasone production, Halometasone plant cost, Halometasone production costs, and the overall Halometasone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Halometasone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Halometasone is a high-potency synthetic corticosteroid, mainly utilised in pharmaceutical production as an active pharmaceutical ingredient (API). It is used for formulating topical creams, ointments, and gels used to treat inflammatory skin conditions such as eczema, psoriasis, dermatitis, and allergic reactions. These formulations utilise its strong anti-inflammatory, antipruritic, and vasoconstrictive properties to reduce redness, swelling, and itching, which makes it an important component in dermatological product lines.
Halometasone market growth is driven by the rising prevalence of inflammatory skin conditions like eczema, psoriasis, and dermatitis, fuelled by environmental factors, pollution, and lifestyle changes. Increasing awareness of skin health, as well as an ageing global population more susceptible to chronic dermatological issues, boosts demand for effective topical corticosteroid treatments utilising halometasone.
Advancements in pharmaceutical formulations, such as improved absorption and reduced side effects, along with expanded healthcare access, e-commerce distribution, and R&D investments, contribute to the market demand. Industrial halometasone procurement is influenced by factors such as supplier reliability, impurity profiles from synthesis or degradation (managed via HPLC/GC testing), and micronised grades for formulation needs. Furthermore, geographic sourcing from China, Italy, and India affects logistics, which impacts the overall procurement.
Raw Material for Halometasone Production
According to the Halometasone production plant project report, the raw material for Halometasone production includes 9α-hydroxy-16α-methylprednisolone.
Production Process of Halometasone
The extensive Halometasone production cost report consists of the following major industrial production process:
- Production via a multi-step chemical pathway: The production process of Halometasone starts from the steroid precursor 9α-hydroxy-16α-methylprednisolone. The process proceeds through the initial dehydration to form the Δ9(11)-unsaturated intermediate by eliminating the 11β-hydroxyl group, followed by stereoselective introduction of the 6α-fluoro substituent via directed fluorination. In the next step, the Δ9(11) double bond undergoes epoxidation and regioselective ring-opening with a fluorine source to install the 9α-fluoro and 11β-hydroxyl groups, while chlorination targets the 2-position on the A-ring under controlled conditions. The process concludes with purification, via crystallisation from methanol-water or ethanol-THF mixtures to yield high-purity halometasone.
Properties of Halometasone
Halometasone (C22H27ClF2O5) is a synthetic tri-halogenated corticosteroid with a molecular weight of 444.9 g/mol. It appears as a white to off-white solid powder. It has a melting point in the range of 220-222 degree Celsius (with decomposition), an estimated density of 1.42 g/cm³, and a boiling point of 600.5 degree Celsius at standard pressure. It has moderate lipophilicity, indicated by an XLogP3 value of 2.6 and three hydrogen bond donors. It is chemically stable under refrigerated storage (2-8 degree Celsius). It has key functional groups including a 2-chloro, 6α,9-difluoro substitution on the pregna-1,4-diene-3,20-dione steroid nucleus with 11β,17,21-trihydroxy and 16α-methyl moieties, enabling potent anti-inflammatory activity while requiring micronisation (≤30 μm) for pharmaceutical formulations.
